STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.

ABSTRACT:

Introduction

Although the combination of anti-programmed cell death-1 or anti-programmed cell death ligand-1 (PD-L1) with platinum chemotherapy is a standard of care for NSCLC, clinical responses vary. Even though predictive biomarkers (which include PD-L1 expression, tumor mutational burden, and inflamed immune microenvironment) are validated for immunotherapy, their relevance to chemoimmunotherapy combinations is less clear. We have recently reported that activation of the stimulator of interferon genes (STING) innate immune pathway enhances immunotherapy response in SCLC. Here, we hypothesize that STING pathway activation may predict and underlie predictive correlates of antitumor immunity in NSCLC.

Methods

We analyzed transcriptomic and proteomic profiles in two NSCLC co

SUBMITTER: Della Corte CM 

PROVIDER: S-EPMC7202130 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature